IONIS PHARMACEUTICALS INC — Director's Dealing 2018

Jan 17, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IONIS PHARMACEUTICALS INC (IONS)
CIK: 0000874015
Period of Report: 2018-01-15

Reporting Person: O'NEIL PATRICK R. (SVP, Legal & General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-01-15	Common Stock	M	6663	—	Acquired	17149	Direct
2018-01-16	Common Stock	S	2697	$51.76	Disposed	14452	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-15	Restricted Stock Units	$	A	12141	Acquired		Common Stock (12141)	Direct
2018-01-15	Restricted Stock Units	$	M	6663	Disposed		Common Stock (6663)	Direct

Footnotes

F1: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F2: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.759 to $51.761, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

F4: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.

F5: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F6: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.